The Quantellect read.As of Nov 19, 2026, 7 active firms cover Novo Nordisk A/S: 1 rate it Buy or better, 5 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets span $40.00 to $73.50, a moderate spread. The average target of $48.63 sits 25% above the current $38.85. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $5.79 next quarter toward $22.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Neutral
Strong Buy00%
Buy114%
Neutral571%
Sell114%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$48.63
+25.1% upside
Average target across 4 active firms as of Nov 19, 2026 vs $38.86 current
Highest Target$73.50
Average Target$48.63
Lowest Target$40.00
Detailed analyst forecasts for NVO
Showing 1–6 of 6 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 1 of 7 active firms rate NVO a Buy (5 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NVO EPS & revenue forecast
EPS · NEXT QUARTER
$5.79
Range $5.79 – $5.79 · 1 analysts · -13% YoY
Next period, 1 analysts expect Novo Nordisk A/S to earn $5.79 a share (range $5.79 – $5.79), versus $6.63 a year earlier. Full-year consensus is $23.56, growing to $22.89 the year after.
REVENUE · NEXT QUARTER
$73.3B
Range $73.3B – $73.3B · 1 analysts · +5% YoY
Revenue is expected to reach $73.3B (range $73.3B – $73.3B), +4.6% year-over-year. Full-year consensus is $309.6B, rising to $313.1B next year.
Top analysts covering Novo Nordisk A/S
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVO.
#1
ED
Evan David Seigerman
BMO Capital
Neutral
$40.00+2.9% to target
Coverage
—
+ Follow
#2
TB
Thibault Boutherin
Morgan Stanley
Sell
$40.00+2.9% to target
Coverage
—
+ Follow
#3
JQ
James Quigley
Goldman Sachs
Neutral
$44.00+13.2% to target
Coverage
—
+ Follow
#4
Rajesh Kumar
HSBC
Neutral
$54.00+39.0% to target
Coverage
—
+ Follow
#5
KH
Kerry Holford
Berenberg Bank
Neutral
$47.00+21.0% to target
Coverage
—
+ Follow
NVO stock forecast FAQ
What is NVO's average 12-month price target?+
The 4 active firms with a live target average $48.63 for Novo Nordisk A/S over the next 12 months, ranging from a $73.50 high to a $40.00 low, as of Nov 19, 2026.
Is NVO stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 7 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 5 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NVO?+
The Street-high target is $73.50, and the Street-low is $40.00 (BMO Capital). The average of all 4 active-firm targets is $48.63.
How many active Wall Street firms cover NVO?+
7 active firms have a recognized rating on Novo Nordisk A/S as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NVO?+
Among analysts who currently cover NVO, Evan David Seigerman of BMO Capital has the strongest overall Quantellect track record. Their current call is Neutral with a $40.00 target.
What is Novo Nordisk A/S's projected EPS for next quarter?+
The consensus estimate is $5.79 per share (range $5.79 – $5.79) across 1 analysts. Full-year EPS is projected at $23.56, rising to $22.89 the following year.
How much revenue is Novo Nordisk A/S expected to report next quarter?+
Consensus revenue is $73.3B (range $73.3B – $73.3B). Full-year revenue is projected at $309.6B, growing to $313.1B next year.
Have analysts been upgrading or downgrading NVO lately?+
As of Nov 19, 2026, 1 of 7 active firms rate NVO a Buy (5 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.